Abstract: A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.

Abstract: Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease.

Abstract: A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.

Abstract: A method of detecting sphingosines and platelet activation is disclosed.

Abstract: Toner for developing electrostatic images contains at least a colorant and a charge control dye in a binding resin which is the main component thereof, the toner having a surface dye density of less than 5.times.10.sup.-3 g/g and containing a monomer having a charge control polar group within the range of 0.01 to 5 weight percent based on the weight of the toner. The binding resin is preferably formed from at least one kind of monomer selected from a group consisting of vinyl aromatic monomers, acrylic type monomers, vinyl ester type monomers, vinyl ether type monomers, diolefin type monomers and monoolefin type monomers, and further preferably from at least one kind of monomer selected from a group consisting of styrene, ester acrylate and ester methacrylate. Also, the binding resin may be formed from at least one kind of monomer selected from a group consisting of polyester, phenol and epoxy resins. It is desirable that the colorant be used in 0.

Abstract: Spheroidal toner for developing electrostatic images is composed of a binding resin as its main component in which at least carbon black and a dispersion stabilizer for the carbon black are contained, the conductivity of the toner being in the range of 5.times.10.sup.-11 to 5.times.10.sup.-9 S/cm. The conductivity of the toner is preferably within the range of 4.times.10.sup.-10 to 5.times.10.sup.-9 S/cm. It is also desirable that the dispersion stabilizer be composed of at least one selected from the group consisting of oil-soluble dyes, coupling agents, and surfactants, and that according to Wadel's practical spheroidicity, the toner be within the range of 0.95 to 1.0.